Expertise in
28
conditions

Dr. Feng Jiang

Hematology | Oncology
Promedica Physicians Hematology/Oncology Associates-Sylvania
5308 Harroun Rd Ste 55, 
Sylvania, OH 
Offers Telehealth
23 Years of Experience
Expertise in
28
conditions
Promedica Physicians Hematology/Oncology Associates-Sylvania
5308 Harroun Rd Ste 55, 
Sylvania, OH 

Overview

Feng Jiang is a Hematologist and an Oncologist in Sylvania, Ohio. Dr. Jiang has been practicing medicine for over 23 years is highly rated in 28 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Childhood Iron Deficiency Anemia.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MI

Hospital Affiliations

Promedica Charles And Virginia Hickman Hospital
Promedica Toledo Hospital
Promedica Monroe Regional Hospital
Insight Hospital And Medical Center Coldwater

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Promedica Physicians Hematology/Oncology Associates-Sylvania
5308 Harroun Rd Ste 55, Sylvania, OH 43560
Other Locations
ProMedica Hickman Infusion Center
5640 N Adrian Hwy # 1, Adrian, MI 49221

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 4 Less Clinical Trials

27 Total Publications

Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Journal: Neuro-oncology practice
Published: March 20, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Kelly Walkovich
Hematology | Oncology
Expertise in
31
conditions
Dr. Kelly Walkovich
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (26.2 miles away)
734-936-9814
Languages Spoken:
English
See accepted insurances

Kelly Walkovich is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Walkovich is highly rated in 31 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Reticulohistiocytoma.

Expertise in
5
conditions
Dr. Steven Pipe
Hematology | Oncology
Expertise in
5
conditions
Dr. Steven Pipe
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (26.2 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances

Steven Pipe is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Pipe is highly rated in 5 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilia B, Blood Clots, and Von Willebrand Disease (VWD).

Expertise in
23
conditions
Dr. Rajen Mody
Hematology | Oncology
Expertise in
23
conditions
Dr. Rajen Mody
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (26.2 miles away)
734-936-9814
Languages Spoken:
English
See accepted insurances

Rajen Mody is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Mody is highly rated in 23 conditions, according to our data. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Feng Jiang

How do I make an appointment with Dr. Feng Jiang?

You can book an appointment with Dr. Feng Jiang by calling their office at 419-824-6599. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Feng Jiang a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Feng Jiang is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Feng Jiang specialize in?

While Dr. Feng Jiang is a Hematology, they have specific expertise in Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Feng Jiang participate in research or clinical trials?

Yes. Dr. Feng Jiang has published 27 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Feng Jiang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Feng Jiang accept my insurance?

Dr. Feng Jiang accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 419-824-6599 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jiang's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile